If a patient on the combined oral contraceptive pill missed two or more pills and has had unprotected sexual intercourse during the pill-free period or week 1 of the pill packet, emergency contraception should be considered. However, in this case, the patient has only missed one pill on day 9 and does not require emergency contraception or a pregnancy test. If the patient had missed two pills during days 1-7 of the pill packet and had unprotected sex, emergency contraception would be necessary. The choice of emergency contraception depends on various factors, including the timing of the unprotected intercourse event, other medications the patient may be taking, and her preferences. Offering to insert a copper coil to prevent pregnancy would be inappropriate in this case. However, if the patient was having trouble remembering to take her pill correctly and wished to consider a long-acting contraceptive, options such as intrauterine devices, subnormal contraceptive implants, and the contraceptive injection could be discussed. It is important to note that the contraceptive injection cannot be used as a form of emergency contraception.

Missed Pills in Combined Oral Contraceptive Pill

When taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol, it is important to know what to do if a pill is missed. The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their recommendations in recent years. If one pill is missed at any time in the cycle, the woman should take the last pill even if it means taking two pills in one day and then continue taking pills daily, one each day. No additional contraceptive protection is needed in this case.

However, if two or more pills are missed, the woman should take the last pill even if it means taking two pills in one day, leave any earlier missed pills, and then continue taking pills daily, one each day. In this case, the woman should use condoms or abstain from sex until she has taken pills for 7 days in a row. If pills are missed in week 1 (Days 1-7), emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week 1. If pills are missed in week 2 (Days 8-14), after seven consecutive days of taking the COC there is no need for emergency contraception.

If pills are missed in week 3 (Days 15-21), the woman should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of 7 days on, 7 days off. It is important to follow these guidelines to ensure the effectiveness of the COC in preventing pregnancy.

Management Options for Urge Incontinence: Medications, Procedures, and Desmopressin

Urge incontinence is a common condition that can significantly impact a patient’s quality of life. While conservative treatments such as pelvic floor exercises and bladder training are often the first line of management, some patients may require additional interventions. Here are some options for managing urge incontinence:

Oxybutinin: This anticholinergic medication is often used as first-line treatment for urge incontinence that has not responded to conservative measures. It works by inhibiting muscarinic action on acetylcholine receptors, preventing muscle contraction. However, it is contraindicated in certain patients and can cause side effects such as dry mouth and constipation.

Percutaneous sacral nerve stimulation: This procedure involves a small stimulator that delivers stimulation to the sacral nerve, leading to contraction of the external sphincter and pelvic floor muscles. It is reserved for patients who have failed other treatments or cannot perform intermittent self-catheterization.

Augmentation cystoplasty: This surgical procedure is reserved for severe cases of urge incontinence that have not responded to other management options. It involves resecting a segment of the small bowel and suturing it to the bladder to increase its size. However, it is associated with numerous complications and requires follow-up.

Botulinum toxin: This is the first-line invasive management for patients who have not improved on anticholinergic medication or do not want drug therapy. It is injected into the bladder to inhibit the release of acetylcholine and provide symptom relief for up to six months.

Desmopressin: This synthetic analogue of antidiuretic hormone is used as second-line management for nocturia in patients with urge incontinence. It works by signaling the transportation of aquaporins in the collecting ducts of the kidney, leading to water reabsorption and less urine production. However, it is contraindicated in certain patients and can cause side effects such as hyponatremia and fluid retention.

In summary, there are several options for managing urge incontinence, ranging from medications to procedures. It is important to consider the patient’s individual needs and contraindications when selecting a treatment plan.

Thrush, also known as candidal infection, is a prevalent condition that is often triggered or worsened by recent use of antibiotics. Therefore, it is the most probable reason for the symptoms in this case. It should be noted that urinary tract infections do not typically cause vaginal discharge.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

The appropriate medical management for a miscarriage involves administering vaginal misoprostol alone. This is a prostaglandin analogue that stimulates uterine contractions, expediting the passing of the products of conception. Oral methotrexate and oral mifepristone alone are not suitable for managing a miscarriage, as they are used for ectopic pregnancies and terminations of pregnancy, respectively. The combination of oral misoprostol and oral mifepristone, as well as vaginal misoprostol and oral mifepristone, are also not recommended due to limited evidence of their efficacy. The current recommended approach is to use vaginal misoprostol alone, as it limits side effects and has a strong evidence base.

Management Options for Miscarriage

Miscarriage can be a difficult and emotional experience for women. In the 2019 NICE guidelines, three types of management for miscarriage were discussed: expectant, medical, and surgical. Expectant management involves waiting for a spontaneous miscarriage and is considered the first-line option. However, if it is unsuccessful, medical or surgical management may be offered.

Medical management involves using tablets to expedite the miscarriage. Vaginal misoprostol, a prostaglandin analogue, is used to cause strong myometrial contractions leading to the expulsion of tissue. It is important to advise patients to contact their doctor if bleeding does not start within 24 hours. Antiemetics and pain relief should also be given.

Surgical management involves undergoing a surgical procedure under local or general anaesthetic. The two main options are vacuum aspiration (suction curettage) or surgical management in theatre. Vacuum aspiration is done under local anaesthetic as an outpatient, while surgical management is done in theatre under general anaesthetic. This was previously referred to as ‘Evacuation of retained products of conception’.

It is important to note that some situations are better managed with medical or surgical management, such as an increased risk of haemorrhage, being in the late first trimester, having coagulopathies or being unable to have a blood transfusion, previous adverse and/or traumatic experience associated with pregnancy, evidence of infection, and more. Ultimately, the management option chosen should be based on the individual patient’s needs and preferences.

The most appropriate investigation for a suspected ectopic pregnancy is a transvaginal ultrasound. In this case, the patient’s symptoms and examination findings suggest an ectopic pregnancy, making transvaginal ultrasound the investigation of choice. Transabdominal ultrasound is less sensitive and therefore not ideal. NAAT, which is used to detect chlamydia, is not relevant in this case as the patient’s history suggests a higher likelihood of ectopic pregnancy rather than infection. Laparoscopy, which is used to diagnose endometriosis, is not indicated based on the clinical presentation.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Management of Women after Treatment for Cervical Intra-epithelial Neoplasia

After treatment for cervical intra-epithelial neoplasia (CIN) at colposcopy, women undergo a repeat smear six months later to check for any residual disease. The management plan following this test of cure depends on the results.

HPV Test of Cure in Six Months, If Negative Recall in Three Years

If the test is negative for dyskaryosis and high-risk HPV (HR HPV), the woman is recalled in three years, regardless of her age. If the test remains negative at the three-year mark, she can return to routine screening based on her age group.

HPV Test of Cure in Six Months, If Negative Recall in Five Years

Even if the patient is 54 years old, women who have a negative HPV test of cure at six months are recalled for a smear three years later. If this is negative, she will then be returned to routine recall every five years.

HPV Test of Cure in Three Months, If Negative Recall in Five Years

The screening test should not be repeated at three months, as this is not enough time for the cervical tissue to heal. Reactive/healing changes in the cytological sample may give a false impression of dyskaryosis. Instead, a HPV test of cure is performed at six months, and if negative, the woman is recalled for routine screening every five years.

Refer Back to Routine Screening, Repeat in Three/Five Years

If the HPV test of cure is positive for HPV or there is evidence of moderate/severe dyskaryosis, the woman is referred back to colposcopy for further investigation. If the test is negative, she is referred back to routine screening and recalled in three or five years, depending on the scenario.

Differential Diagnosis for a Drowsy, Septic Patient with Menstrual Period: A Case Study

A female patient presents with evidence of severe sepsis during her menstrual period. The cause is not immediately apparent on examination or lumbar puncture, but her blood work indicates an infective process with elevated white cell count, reduced platelet count, and acute kidney injury. The differential diagnosis includes toxic shock syndrome, which should prompt an examination for a retained tampon and treatment with a broad-spectrum antibiotic. Bacterial meningitis is ruled out due to a normal lumbar puncture. Gram-negative urinary tract infection is unlikely without a history of urinary symptoms or definitive evidence in the urine. Appendicitis is not consistent with the patient’s history or physical exam. Viral meningitis is also unlikely due to the absence of headache and neck stiffness, as well as a normal lumbar puncture. With increased public awareness of the danger of retained tampons, toxic shock syndrome is becoming a rare occurrence.

Understanding the Different Types of Urinary Incontinence in Women

Urinary incontinence is a common condition that affects many women. There are different types of urinary incontinence, each with its own causes and treatment options. The most common type of incontinence in women is genuine stress incontinence, which is caused by sphincter incompetence and leads to leakage of small amounts of urine on stress, such as sneezing, standing, laughing, and coughing.

To diagnose incontinence, common investigations include a midstream urine specimen, frequency volume chart, filling urodynamic assessment, and voiding urodynamic assessment. Treatment options vary depending on the patient’s wishes, desire for future children, and severity of symptoms. Conservative treatment involves pelvic floor exercises, vaginal cones, and drugs such as estrogen. Surgery is the most effective way of restoring continence, with a cure rate of 80-90%. Procedures include burch colposuspension, anterior repair and bladder buttress, tension-free vaginal tape, and suburethral sling.

Other types of urinary incontinence in women include fistula, which is a rare cause of incontinence caused by pelvic surgery, overactive bladder, which is the second most common type of incontinence, retention with overflow, which is a rare cause of incontinence more common in men, and congenital abnormalities, which is a rare cause of incontinence that is often apparent since early life.

It is important for women to understand the different types of urinary incontinence and seek medical advice if they experience any symptoms. With proper diagnosis and treatment, urinary incontinence can be effectively managed, improving quality of life and overall health.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Diagnosing Gynaecological Malignancies: Understanding the Differences

When a postmenopausal woman presents with vaginal bleeding, pelvic mass, and pelvic lymphadenopathy, it is important to consider the different types of Gynaecological malignancies that could be causing these symptoms. The most likely diagnosis in this case is cervical squamous cell carcinoma, which typically metastasises to the pelvic lymph nodes along the iliac arteries.

While endometrial carcinoma (adenocarcinoma) is the most common Gynaecological malignancy, it would also be a possibility in this patient. Ovarian cancer, the second most common Gynaecological cancer, typically metastasises to the para-aortic lymph nodes and is not associated with vaginal bleeding.

Vulval cancers tend to metastasise to the superficial inguinal node and are unlikely to present with a pelvic mass or vaginal bleeding. Cervical adenocarcinomas are rare and derived from the endocervix, while uterine leiomyosarcoma often extends beyond the uterine serosa and occasionally metastasises to distant organs through blood vessels. However, neither of these malignancies typically present with vaginal bleeding and pelvic lymphadenopathy.

In summary, understanding the differences between the various types of Gynaecological malignancies is crucial in accurately diagnosing and treating patients with these conditions.

Expectant management of an ectopic pregnancy is only suitable for an embryo that is unruptured, <35mm in size, has no heartbeat, is asymptomatic, and has a β-hCG level of <1,000 IU/L and declining. In this case, the woman has a small ectopic pregnancy without cardiac activity and a declining β-hCG level. Therefore, expectant management is appropriate, and the woman should be given safety netting advice and asked to return for a follow-up blood test in 48 hours. Admitting her for 12-hourly β-hCG monitoring is unnecessary, and performing a salpingectomy or salpingostomy is not indicated. Prescribing medical management is also inappropriate in this case. Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test. There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility. Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

postmenopausal Bleeding: Common Causes and Investigations

postmenopausal bleeding can be caused by various factors, including atrophic vaginitis, endometrial atrophy, cervical or endometrial polyps, and endometrial hyperplasia/cancer. Among these causes, endometrial cancer is the most likely. Therefore, investigation for patients with postmenopausal bleeding is typically done in a specialist clinic, with transvaginal ultrasound, hysteroscopy, and biopsy.

However, submucosal fibroids become quiescent following menopause and usually calcify, and there is no evidence of increased risk of endometrial cancer in women with fibroids. On the other hand, ovarian cancer rarely, if ever, presents with postmenopausal bleeding. Cervical ectropion is a condition of young women, and vaginal cancer is very rare and usually presents with vaginal discharge.

In summary, postmenopausal bleeding should be investigated thoroughly to rule out any underlying serious conditions, such as endometrial cancer.

Misconceptions about Menopause and Reproduction

Menopause is often associated with misconceptions about reproductive health. Here are some common misconceptions and the correct information:

Common Misconceptions about Menopause and Reproduction

1. Menopause is associated with a decrease in follicle-stimulating hormone (FSH).
Correction: Menopause is associated with an increase in FSH due to the loss of negative feedback from estrogen on the anterior pituitary.

2. Progesterone is necessary for ovulation to take place.
Correction: Both FSH and luteinizing hormone (LH) are needed for ovulation to take place. Progesterone is necessary for preparing the uterus for implantation.

3. Estrogen concentration peaks during menstruation.
Correction: Estrogen concentration peaks just before ovulation during the follicular phase of the menstrual cycle.

4. Ovarian tissue is the only source of estrogen production.
Correction: While ovarian tissue is the main source of estrogen production, the adrenal cortex and adipose tissue also contribute to estrogen production.

5. Fertilization of the human ovum normally takes place in the uterus.
Correction: Fertilization of the human ovum normally takes place in the outer third of the Fallopian tubes, not the uterus. The fertilized egg then implants in the uterus.

Management of Ectopic Pregnancy: Laparoscopic Salpingostomy

Ectopic pregnancy, defined as pregnancy occurring outside the uterine cavity, is a serious condition that requires prompt diagnosis and management. Laparoscopic salpingostomy is a preferred method of treatment for ectopic pregnancies, but it may not be suitable for all cases.

Diagnosis of ectopic pregnancy can be challenging as it presents with non-specific symptoms such as lower abdominal/pelvic pain, vaginal discharge, and urinary symptoms. A urinary pregnancy test and an ultrasound scan are necessary to confirm the diagnosis. In emergency cases where the patient is haemodynamically unstable, laparotomy may be necessary.

Laparoscopic salpingectomy, the removal of the tube containing the ectopic pregnancy, is the gold standard for treating ectopic pregnancies. However, if the patient has only one Fallopian tube, laparoscopic salpingostomy, where the tube is incised, the ectopic removed, and the tube repaired, is preferred to preserve the patient’s chances of conceiving naturally in the future.

A single intramuscular dose of methotrexate may be used as medical management of an ectopic pregnancy, but only if certain conditions are met. These include the absence of significant pain, an unruptured ectopic pregnancy, and a serum βhCG level of <1500 iu/l. In cases where right iliac fossa pain is present in a woman of reproductive age, associated with vaginal discharge, cervical excitation, and the last menstrual period of >4 weeks before, ectopic pregnancy should be treated as the primary diagnosis until proven otherwise. Referral to the surgical team may be necessary to rule out appendicitis.

In conclusion, laparoscopic salpingostomy is a suitable method of treatment for ectopic pregnancies in patients with only one Fallopian tube. Early diagnosis and prompt management are crucial in ensuring the best possible outcome for the patient.

The appropriate answer is that the woman cannot use the pill anymore due to an unacceptably high clinical risk. She has developed systemic lupus erythematosus (SLE) with positive antiphospholipid antibodies, which is classified as UK Medical Eligibility Criteria for Contraceptive Use UKMEC 4, meaning it is an absolute contraindication. The risks of arterial and venous thrombosis would be too high if she were to restart the combined pill, and alternative contraceptive options should be considered. It is important to note that both SLE with positive antiphospholipid antibodies and isolated presence of antiphospholipid antibodies are classified as UKMEC 4 conditions, but not the diagnosis of antiphospholipid syndrome. The advantages of using the pill generally outweigh the risks is an incorrect answer, as it is equivalent to UKMEC 2. The correct answer would be applicable if the woman did not test positive for any of the three antiphospholipid antibodies or if she did not test positive again after 12 weeks. The risks usually outweigh the advantages of using the combined pill is also incorrect, as it is equivalent to UKMEC 3. Lastly, there is no risk or contraindication to her restarting the combined pill is an incorrect answer, as it is equivalent to UKMEC 1.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, Breastfeeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

1. The initial stage of endometrial cancer typically involves a hysterectomy and bilateral salpingo-oophorectomy.
2. Diagnosis of endometrial cancer requires an endometrial biopsy.
3. Radiotherapy is the preferred treatment over chemotherapy, especially for high-risk patients after a hysterectomy or in cases of pelvic recurrence.
4. Lymphadenectomy is not typically recommended as a routine procedure.
5. Progestogens are no longer commonly used in the treatment of endometrial cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Understanding Ovarian Hyperstimulation Syndrome

Ovarian hyperstimulation syndrome (OHSS) is a potential complication that can occur during infertility treatment. This condition is believed to be caused by the presence of multiple luteinized cysts in the ovaries, which can lead to high levels of hormones and vasoactive substances. As a result, the permeability of the membranes increases, leading to fluid loss from the intravascular compartment.

OHSS is more commonly seen following gonadotropin or hCG treatment, and it is rare with Clomiphene therapy. Approximately one-third of women undergoing in vitro fertilization (IVF) may experience a mild form of OHSS. The Royal College of Obstetricians and Gynaecologists (RCOG) has classified OHSS into four categories: mild, moderate, severe, and critical.

Symptoms of OHSS can range from abdominal pain and bloating to more severe symptoms such as thromboembolism and acute respiratory distress syndrome. It is important to monitor patients closely during infertility treatment to detect any signs of OHSS and manage the condition appropriately. By understanding OHSS and its potential risks, healthcare providers can work to minimize the occurrence of this complication and ensure the safety of their patients.

To manage unscheduled bleeding, which is a common side effect of Nexplanon, a 3-month course of the combined oral contraceptive pill may be prescribed. This will not only provide additional contraception but also make periods lighter and more regular. Prescribing a progesterone-only pill is not recommended as it can also cause irregular bleeding. A single dose of intramuscular methotrexate is not appropriate as the patient is not showing any symptoms of an ectopic pregnancy. Urgent referral for endometrial cancer is also not necessary as the patient’s age and symptoms suggest that the bleeding is most likely due to the contraceptive implant.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progesterone hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

The addition of a progesterone to HRT raises the likelihood of developing breast cancer, making this the accurate response.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Common Causes of Vaginal Discharge: Symptoms and Treatment

Bacterial vaginosis, Trichomonas vaginalis, Candidiasis, gonorrhoeae, and Pelvic inflammatory disease are some of the most common causes of vaginal discharge in women.

Bacterial vaginosis is caused by an overgrowth of anaerobic bacteria and loss of lactobacilli in the vagina. It presents with a grey-white, thin discharge with a fishy odour and an increased vaginal pH. Metronidazole is the treatment of choice.

Trichomonas vaginalis is a sexually transmitted infection that presents with a yellow-green discharge and an erythematosus cervix with a punctate exudate.

Candidiasis is a fungal infection associated with pruritus, burning, erythema, and oedema of the vestibule. The vaginal discharge is thick, curd-like, and white.

gonorrhoeae can be asymptomatic or present with abdominal pain, mucopurulent discharge, cervicitis, dyspareunia, or abnormal bleeding.

Pelvic inflammatory disease is the result of an ascending infection and presents with dyspareunia, lower abdominal pain, menstrual irregularities, irregular bleeding, and a blood stained, purulent vaginal discharge. Cervicitis and cervical excitation are also present.

Proper diagnosis and treatment are essential to prevent complications and improve the quality of life of affected women.